Shilpa Pharma Lifesciences Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is SUNITINIB MALATE, with a corresponding US DMF Number 33085.
Remarkably, this DMF maintains an Active status since its submission on September 19, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 27, 2018, and payment made on October 29, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II